Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)

Organon

Status and phase: Completed; Phase 3

Conditions: Hypercholesterolemia; Coronary Disease

Treatments: Drug: MK0653, ezetimibe; Drug: Comparator: ezetimibe, placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092599

0653-801

2004_039

Details and patient eligibility

About

This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.

Full description

The duration of treatment is 10 weeks.

Enrollment: 410 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with elevated cholesterol and coronary heart disease

Exclusion criteria

• Patients who do not meet specific cholesterol levels as required by the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind